VBIV

VBI Vaccines Inc. [VBIV] Stock Forecast

Q: What is VBI Vaccines Inc. stock symbol ?

VBI Vaccines Inc. is a US stock, located in Cambridge of Ma and trading under the symbol VBIV

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

VBIV Stock Summary

Earnings have grown 71.47% per last year.

Has a high level of debt. Debt-to-Equity ratio of 2.6 is considered high.

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 years (Yearly statements)

Does not have any significance market cap ($13.74M)

VBIV has less than 1 year of cash runway

Top 10 Correlated Stocks

VBIV

In the News

VBIV Financial details

Company Rating

Sell

Market Cap

13.74M

Income

-122.13M

Revenue

8.12M

Book val./share

0.94

Cash/share

1.67

Dividend

Dividend %

Employees

190

Optionable

Shortable

Yes

Earnings

12 Apr 2024

P/E

-0.11

Forward P/E

PEG

-0.02

P/S

1.82

P/B

0.67

P/C

0.39

P/FCF

-0.21

Quick Ratio

0.46

Current Ratio

0.65

Debt / Equity

2.6

LT Debt / Equity

0.07

EPS (TTM)

-12.78

EPS next Y

EPS next Q

EPS this Y

91.46%

EPS next Y

EPS next 5Y

EPS last 5Y

-10.84%

Revenue last 5Y

-20.25%

Revenue Q/Q

820%

EPS Q/Q

-81.27%

SMA20

SMA50

SMA100

Inst Own

Inst Trans

ROA

-121%

ROE

-354%

ROC

-3.73%

Gross Margin

-59%

Oper. Margin

-1083%

Profit Margin

-1504%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

0.45-3.86

52W High

52W Low

RSI

Rel Volume

0.33

Avg Volume

437.28K

Volume

144.54K

Perf Week

8.17%

Perf Month

11.9%

Perf Quarter

10.56%

Perf Half Y

18%

Beta

1.917

Volatility

0.02%, 0.07%

Prev Close

3.06%

Price

0.649

Change

3.02%

VBIV Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	1.53	0.56	0.15	0.07	0.13
Net income per share	-29.06	-14.02	-6.5	-8.55	-16.37
Operating cash flow per share	-20.81	-12.23	-6.47	-4.7	-8.56
Free cash flow per share	-23.55	-13.16	-6.6	-4.93	-9.07
Cash per share	27.09	11.1	16.37	14.32	7.28
Book value per share	44.85	22.17	23.6	16.93	7.45
Tangible book value per share	14.45	6.35	14.75	9.36	0.43
Share holders equity per share	44.85	22.17	23.6	16.93	7.45
Interest debt per share	7.9	4.49	2.83	4.3	6.53
Market cap	105.04M	164.84M	600.24M	596.58M	100.72M
Enterprise value	59.79M	135.47M	507.36M	506.68M	90.32M
P/E ratio	-1.65	-2.95	-12.69	-8.21	-0.71
Price to sales ratio	31.31	74.22	565.73	945.45	93.09
POCF ratio	-2.31	-3.38	-12.76	-14.95	-1.37
PFCF ratio	-2.04	-3.15	-12.49	-14.24	-1.29
P/B Ratio	1.07	1.87	3.5	4.15	1.57
PTB ratio	1.07	1.87	3.5	4.15	1.57
EV to sales	17.82	60.99	478.19	802.98	83.47
Enterprise value over EBITDA	-1.01	-2.94	-11.63	-7.45	-1.1
EV to operating cash flow	-1.31	-2.78	-10.78	-12.7	-1.23
EV to free cash flow	-1.16	-2.59	-10.56	-12.09	-1.16
Earnings yield	-0.61	-0.34	-0.08	-0.12	-1.4
Free cash flow yield	-0.49	-0.32	-0.08	-0.07	-0.77
Debt to equity	0.14	0.18	0.1	0.22	0.81
Debt to assets	0.1	0.13	0.09	0.15	0.34
Net debt to EBITDA	0.76	0.64	2.13	1.32	0.13
Current ratio	2.64	1.58	7.61	4	2.1
Interest coverage	-18.56	-23.86	-16.11	-14.38	-20.42
Income quality	0.72	0.89	1.02	0.57	0.65
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	6.2	6.34	19.46	60.75	51.87
Research and developement to revenue	11.47	11.86	14	31	14.33
Intangibles to total assets	0.48	0.52	0.31	0.31	0.39
Capex to operating cash flow	0.13	0.08	0.02	0.05	0.06
Capex to revenue	-1.79	-1.65	-0.94	-3.16	-4.01
Capex to depreciation	-11.06	-3.05	-0.61	-1.09	-2.11
Stock based compensation to revenue	0.99	1.77	4.98	15.26	8.96
Graham number	171.25	83.61	58.75	57.07	52.4
ROIC	-0.54	-0.51	-0.23	-0.4	-0.85
Return on tangible assets	-0.89	-0.94	-0.33	-0.5	-1.49
Graham Net	9.27	2.75	11.35	6.66	-2.9
Working capital	38.35M	17.21M	114.69M	97.7M	40.75M
Tangible asset value	31.62M	25.29M	107.29M	79.53M	3.69M
Net current asset value	22.26M	13.02M	94.37M	63.89M	-13.23M
Invested capital	0.14	0.18	0.1	0.22	0.81
Average receivables	99.5K	128.5K	139K	42.5K	51K
Average payables	3.93M	3.59M	2.43M	4.01M	8.63M
Average inventory	849.5K	993K	1.61M	2.36M	4.59M
Days sales outstanding	6.09	33.03	26.49	4.63	31.71
Days payables outstanding	490.15	52.04	148.66	145.05	419.93
Days of inventory on hand	73.74	49.64	85.68	87.3	213.61
Receivables turnover	59.91	11.05	13.78	78.88	11.51
Payables turnover	0.74	7.01	2.46	2.52	0.87
Inventory turnover	4.95	7.35	4.26	4.18	1.71
ROE	-0.65	-0.63	-0.28	-0.5	-2.2
Capex per share	-2.74	-0.92	-0.14	-0.23	-0.5

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric	2022-09-30	2022-12-31	2023-03-31	2023-06-30	2023-09-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.04	0.03	0.06	0.08	0.31
Net income per share	-3.26	-2.28	-4.35	-5.18	-0.97
Operating cash flow per share	-2.01	-2.21	-2.52	-2.23	-0.38
Free cash flow per share	-2.16	-2.38	-2.58	-2.24	-0.38
Cash per share	9.71	7.28	4.69	2.42	1.67
Book value per share	9.74	7.45	5.23	1.02	0.94
Tangible book value per share	2.79	0.43	-1.81	-3.92	-0.84
Share holders equity per share	9.74	7.45	5.23	1.02	0.94
Interest debt per share	6.18	6.28	6.31	6.34	2.37
Market cap	183.36M	100.72M	77.48M	28.32M	14.1M
Enterprise value	151.71M	90.32M	89.46M	60.04M	28.95M
P/E ratio	-1.63	-1.28	-0.52	-0.16	-0.17
Price to sales ratio	578.43	343.76	159.75	39.34	2.13
POCF ratio	-10.61	-5.29	-3.58	-1.47	-1.77
PFCF ratio	-9.87	-4.91	-3.49	-1.47	-1.75
P/B Ratio	2.19	1.57	1.72	3.24	0.71
PTB ratio	2.19	1.57	1.72	3.24	0.71
EV to sales	478.6	308.25	184.45	83.38	4.37
Enterprise value over EBITDA	-7.38	-4.45	-4.84	-3.71	-2.87
EV to operating cash flow	-8.78	-4.74	-4.13	-3.13	-3.64
EV to free cash flow	-8.17	-4.41	-4.03	-3.12	-3.59
Earnings yield	-0.15	-0.19	-0.48	-1.58	-1.45
Free cash flow yield	-0.1	-0.2	-0.29	-0.68	-0.57
Debt to equity	0.62	0.81	1.16	6.01	2.6
Debt to assets	0.3	0.34	0.41	0.6	0.51
Net debt to EBITDA	1.54	0.51	-0.65	-1.96	-1.47
Current ratio	2.77	2.1	1.75	1.15	0.65
Interest coverage	-16.95	-11.57	-10.1	-18.41	6.53
Income quality	0.69	0.9	0.78	0.43	0.39
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	44.86	54.22	0	15.16	0
Research and developement to revenue	15.72	8.59	6.5	4.57	0.23
Intangibles to total assets	0.35	0.39	0.47	0.48	0.37
Capex to operating cash flow	0.08	0.08	0.02	0	0.01
Capex to revenue	-4.1	-4.96	-1.1	-0.07	-0.02
Capex to depreciation	-2.47	-2.79	-1.05	-0.1	-0.23
Stock based compensation to revenue	7.61	7.94	4.15	2.33	0.23
Graham number	26.73	19.56	22.62	10.88	4.52
ROIC	-0.17	-0.17	-0.26	-0.6	-0.13
Return on tangible assets	-0.25	-0.21	-0.55	-0.97	-0.32
Graham Net	0.01	-2.54	-4.48	-6.28	-1.96
Working capital	61.54M	40.75M	22.26M	4.22M	-27.05M
Tangible asset value	23.99M	3.69M	-15.61M	-33.78M	-17.84M
Net current asset value	8.02M	-13.23M	-31.6M	-47.69M	-30.75M
Invested capital	0.62	0.81	1.16	6.01	2.6
Average receivables	2.47M	3.3M	2.81M	1.57M	1.01M
Average payables	8.64M	12.32M	11.41M	8.6M	7.18M
Average inventory	4.92M	6.2M	6.68M	6.81M	7.2M
Days sales outstanding	704.67	1.27K	275.38	207.13	4.8
Days payables outstanding	392.94	350.83	248.76	190	249.79
Days of inventory on hand	195.22	178.46	171.15	177.29	268.75
Receivables turnover	0.13	0.07	0.33	0.43	18.76
Payables turnover	0.23	0.26	0.36	0.47	0.36
Inventory turnover	0.46	0.5	0.53	0.51	0.33
ROE	-0.33	-0.31	-0.83	-5.11	-1.03
Capex per share	-0.15	-0.17	-0.06	-0.01	-0.01

VBIV Frequently Asked Questions

What is VBI Vaccines Inc. stock symbol ?

VBI Vaccines Inc. is a US stock , located in Cambridge of Ma and trading under the symbol VBIV

What is VBI Vaccines Inc. stock quote today ?

VBI Vaccines Inc. stock price is $0.649 today.

Is VBI Vaccines Inc. stock public?

Yes, VBI Vaccines Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 437.28K
Market Capitalization 13.74M
Employee 190
CEO Mr. Jeffery R. Baxter FCMA
Headquarters Cambridge,MA,US
IPO Date 2010-04-26
Website https://www.vbivaccines.com

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection. The company's enveloped virus-like particle (eVLP) platform technology allows for the development of eVLP vaccines that mimic the presentation of viruses to elicit a human immune system. Its lead eVLP program candidates include VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study; and VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial. The company also develops coronavirus vaccine candidates, such as VBI-2902 and VBI-2901. In addition, it engages in the development of vaccine platforms and products for licensing to pharmaceutical companies and biotechnology companies. It has collaboration and license agreements with Brii Biosciences Limited; and GlaxoSmithKline Biologicals S.A. The company also has a collaboration with the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. VBI Vaccines Inc. has collaboration with Coalition for Epidemic Preparedness Innovations to advance vaccine candidates against Covid-19 variants. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is headquartered in Cambridge, Massachusetts.